Who is eligible for targeted and immune therapies?
When we’re thinking about using targeted therapies, when we’re thinking about using immune therapies, these are usually in the context of people who have metastatic cancer, or stage 4 disease. That means the cancer has spread outside of the lung. For cancers that are earlier or contained within the lung, our primary therapies are things like surgery and radiation. But when cancers escape outside of the lung, we generally rely on drug therapies. So that’s really where these genetic tests and this PD-L1 test is most important, in that setting.
For more information and to see the full recorded discussion, visit Lung.org/tumor-testing-videos.
Generously supported by AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, Pfizer, and Merck & Co., Inc.
Page last updated: March 22, 2020